Citations

Clear

1526 citation(s) found for "Sun, Yu".

Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin
Fernández, Hugo F. , Sun, Zhuoxin , Litzow, Mark R. , Luger, Selina M. , Paietta, Elisabeth , Racevskis, Janis, Dewald, Gordon W., Ketterling, Rhett P. , Rowe, Jacob M. , Tallman, Martin S. , Lazarus, Hillard M. , Ketterling, Rhett P

Mayo Clinic

Blood | March 18, 2011 | Volume: 117 | Issue: 20 | Pages: 5306-5313

10.1182/blood-2010-09-309229 | PMID 21415269 Get It

AbstractWe report the results of a prospective, randomized phase 3 trial evaluating the use of gemtuzumab ozogamicin (GO) in an intensive consolidation approach in 657 patients 17-60 years of age. Patients in first complete remission (CR1) after cytarabine and standard- or high-dose daunorubicin induction received 2 cycles of consolidation with high-dose cytarabine followed by peripheral blood progenitor cell collection. The 352 patients who entered consolidation were randomized to receive GO (n = 132) or not (n = 138) and then proceeded to autologous hematopoietic cell transplantation (HCT). GO was given to 67 patients. Median follow-up was 50.9 months. Results of the intention-to-treat analysis demonstrated a 4-year disease-free survival (DFS) of 33.6% versus 35.9% (P = .54) and an overall survival (OS) of 41.3% versus 41.9% (P = .52) for those randomized to receive GO versus no GO, respectively. Patients with favorable- and intermediate-risk acute myeloid leukemia (AML) treated with high-dose daunorubicin and autologous HCT had 4-year DFS rates of 60% and 40% and OS rates of 80% and 49.3%, respectively. For younger AML patients in CR1, autologous HCT should be considered in favorable- and intermediate-cytogenetic risk patients who do not have an allogeneic donor. The addition of a single dose of GO in this setting did not improve outcomes. This trial is registered at http://www.clinicaltrials.gov as NCT00049517.
Transcranial Doppler ultrasound blood flow velocity and pulsatility index as systemic indicators for Alzheimer's disease
Roher, Alex E., Garami, Zsolt , Tyas, Suzanne L. , Maarouf, Chera L., Kokjohn, Tyler A., Bëlohlávek, Marek , Vedders, Linda, Connor, Donald J., Sabbagh, Marwan N. , Beach, Thomas G. , Emmerling, Mark R.

Mayo Clinic

Alzheimer's & Dementia | March 16, 2011 | Volume: 7 | Issue: 4 | Pages: 445-455

10.1016/j.jalz.2010.09.002 | PMID 21388892 Get It

BackgroundMultiple lines of evidence suggest that cardiovascular co‐morbidities hasten the onset of Alzheimer's disease (AD) or accelerate its course.MethodsTo evaluate the utility of cerebral vascular physical function and/or condition parameters as potential systemic indicators of AD, transcranial Doppler (TCD) ultrasound was used to assess cerebral blood flow and vascular resistance of the 16 arterial segments comprising the circle of Willis and its major tributaries.ResultsOur study showed that decreased arterial mean flow velocity and increased pulsatility index are associated with a clinical diagnosis of presumptive AD. Cerebral blood flow impairment shown by these parameters reflects the global hemodynamic and structural consequences of a multifaceted disease process yielding diffuse congestive microvascular pathology, increased arterial rigidity, and decreased arterial compliance, combined with putative age‐associated cardiovascular output declines.ConclusionsTCD evaluation offers direct physical confirmation of brain perfusion impairment and might ultimately provide a convenient and a noninvasive means to assess the efficacy of medical interventions on cerebral blood flow or reveal incipient AD. In the near term, TCD‐based direct assessments of brain perfusion might offer the prospect of preventing or mitigating AD simply by revealing patients who would benefit from interventions to improve circulatory system function.
Intracranial atherosclerosis as a contributing factor to Alzheimer's disease dementia
Roher, Alex E., Tyas, Suzanne L. , Maarouf, Chera L., Daugs, Ian D., Kokjohn, Tyler A., Emmerling, Mark R., Garami, Zsolt , Bëlohlávek, Marek , Sue, Lucia I., Beach, Thomas G. , Sabbagh, Marwan Noel

Mayo Clinic

Alzheimer's & Dementia | March 16, 2011 | Volume: 7 | Issue: 4 | Pages: 436-444

10.1016/j.jalz.2010.08.228 | PMID 21388893 Get It

BackgroundA substantial body of evidence collected from epidemiologic, correlative, and experimental studies strongly associates atherosclerotic vascular disease (AVD) with Alzheimer's disease (AD). Depending on the precise interrelationship between AVD and AD, systematic application of interventions used to maintain vascular health and function as a component of standard AD therapy offers the prospect of mitigating the presently inexorable course of dementia. To assess this hypothesis, it is vital to rigorously establish the measures of AVD that are most strongly associated with an AD diagnosis.MethodsA precise neuropathological diagnosis was established for all subjects, using a battery of genetic, clinical, and histological methods. The severity of atherosclerosis in the circle of Willis was quantified by direct digitized measurement of arterial occlusion in postmortem specimens and was compared between AD and nondemented control groups by calculating a corresponding index of occlusion.ResultsAtherosclerotic occlusion of the circle of Willis arteries was more extensive in the AD group than in the nondemented control group. Statistically significant differences were also observed between control and AD groups with regard to Braak stage, total plaque score, total neurofibrillary tangle score, total white matter rarefaction score, brain weight, Mini‐Mental State Examination scores, and apolipoprotein E allelic frequencies.ConclusionsOur results, combined with a consideration of the multifaceted effects of impaired cerebral circulation, suggest an immediate need for prospective clinical trials to assess the efficacy of AD prevention using antiatherosclerotic agents.
A Bivariate Genome-Wide Approach to Metabolic Syndrome
Kraja, Aldi T., Vaidya, Dhananjay , Pankow, James S. , Goodarzi, Mark O., Assimes, Themistocles L. , Sovio, Ulla , Mathias, Rasika A. , Sun, Yan V. , Franceschini, Nora , Absher, Devin , Zhang, Qunyuan, Feitosa, Mary F. , Glazer, Nicole L. , Hartikainen, Anna-Liisa, Knowles, Joshua W. , Iribarren, Carlos , Kral, Brian G. , Yanek, Lisa R. , O’Reilly, Paul F. , McCarthy, Mark I. , Jaquish, Cashell E. , Couper, David , Chakravarti, Aravinda , Becker, Lewis C. , Province, Michael A. , Boerwinkle, Eric , Quertermous, Thomas , Palotie, L, Järvelin, Marjo‐Riitta , Becker, Diane M. , Kardia, Sharon L. R., Rotter, Jerome I. , Chen, Yii-Der Ida , Borecki, Ingrid B. , Goodarzi, Mark O. , Kullo, Iftikhar J. , Guo, Li , Haritunians, Talin , Hartikainen, Anna‐Liisa, North, Kari E. , Psaty, Bruce M. , McCarthy, Mark I , Assimes, Themistocles L , Rotter, Jerome I , Mathias, Rasika A , Pankow, James S , Couper, David , Province, Mike

Mayo Clinic

Diabetes | March 9, 2011 | Volume: 60 | Issue: 4 | Pages: 1329-1339

10.2337/db10-1011 | PMID 21386085 Get It

OBJECTIVE The metabolic syndrome (MetS) is defined as concomitant disorders of lipid and glucose metabolism, central obesity, and high blood pressure, with an increased risk of type 2 diabetes and cardiovascular disease. This study tests whether common genetic variants with pleiotropic effects account for some of the correlated architecture among five metabolic phenotypes that define MetS. RESEARCH DESIGN AND METHODS Seven studies of the STAMPEED consortium, comprising 22,161 participants of European ancestry, underwent genome-wide association analyses of metabolic traits using a panel of ∼2.5 million imputed single nucleotide polymorphisms (SNPs). Phenotypes were defined by the National Cholesterol Education Program (NCEP) criteria for MetS in pairwise combinations. Individuals exceeding the NCEP thresholds for both traits of a pair were considered affected. RESULTS Twenty-nine common variants were associated with MetS or a pair of traits. Variants in the genes LPL, CETP, APOA5 (and its cluster), GCKR (and its cluster), LIPC, TRIB1, LOC100128354/MTNR1B, ABCB11, and LOC100129150 were further tested for their association with individual qualitative and quantitative traits. None of the 16 top SNPs (one per gene) associated simultaneously with more than two individual traits. Of them 11 variants showed nominal associations with MetS per se. The effects of 16 top SNPs on the quantitative traits were relatively small, together explaining from ∼9% of the variance in triglycerides, 5.8% of high-density lipoprotein cholesterol, 3.6% of fasting glucose, and 1.4% of systolic blood pressure. CONCLUSIONS Qualitative and quantitative pleiotropic tests on pairs of traits indicate that a small portion of the covariation in these traits can be explained by the reported common genetic variants.
Abstract LB-186: Genetic variants and risk of lung cancer in never-smokers: A genome-wide association study
Ye, Yuanqing , Chang, Shen‐Chih , Aubry, Marie‐Christine, Aakre, Jeremiah A. , Cunningham, Julie M. , Deschamps, Claude, Jiang, Ruoxiang , Lin, Jie , Marks, Randolph, Su, Li , Vasmatzis, George , Wang, Renyi , Harris, Curtis C. , Spitz, Margaret R., Jen, Jin , Wu, Xifeng , Li, Yafei , Sheu, Chau‐Chyun , Andrade, Mariza de , Wang, Liang , Allen, Mark S. , Chen, Feng , Pankratz, V. Shane , Li, Yan , Sun, Zhifu , Tang, Hui Jun , Zhang, Zuo‐Feng , Christiani, David C. , Yang, Ping

Mayo Clinic

Cancer Research | February 25, 2011 | Volume: 70 | Issue: 8_Supplement | Pages: LB-186-LB-186

10.1158/1538-7445.am10-lb-186 Get It

Abstract Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-186.
Cerebrovascular risk factors and preclinical memory decline in healthy APOE ε4 homozygotes
Caselli, Richard J., Dueck, Amylou C. , Locke, Dona E.C. , Sabbagh, Marwan N. , Ahern, Geoffrey L., Rapcsak, Steven Z. , Baxter, Leslie C. , Yaari, R. , Woodruff, Bryan K. , Hoffman‐Snyder, Charlene , Rademakers, Rosa , Findley, Scott, Reiman, Eric M. , Baxter, Leslie C. , Dueck, A. C. , Locke, Dona E C

Mayo Clinic

Neurology | February 17, 2011 | Volume: 76 | Issue: 12 | Pages: 1078-1084

10.1212/wnl.0b013e318211c3ae | PMID 21325652 Get It

Identification of a Clinically Relevant Androgen-Dependent Gene Signature in Prostate Cancer
Heemers, Hannelore V. , Schmidt, Lucy J., Sun, Zhifu , Regan, Kevin M., Anderson, S. Keith , Duncan, Kelly , Tindall, Donald J., Wang, Dan Michelle , Liu, Song , Ballman, Karla V. , Sun, Zhifu

Mayo Clinic

Cancer Research | February 16, 2011 | Volume: 71 | Issue: 5 | Pages: 1978-1988

10.1158/0008-5472.can-10-2512 | PMID 21324924 Get It

Abstract The androgen receptor (AR) is the principal target for treatment of non–organ-confined prostate cancer (PCa). Androgen deprivation therapies (ADT) directed against the AR ligand–binding domain do not fully inhibit androgen-dependent signaling critical for PCa progression. Thus, information that could direct the development of more effective ADTs is desired. Systems and bioinformatics approaches suggest that considerable variation exists in the mechanisms by which AR regulates expression of effector genes, pointing to a role for secondary transcription factors. A combination of microarray and in silico analyses led us to identify a 158-gene signature that relies on AR along with the transcription factor SRF (serum response factor), representing less than 6% of androgen-dependent genes. This AR-SRF signature is sufficient to distinguish microdissected benign and malignant prostate samples, and it correlates with the presence of aggressive disease and poor outcome. The AR-SRF signature described here associates more strongly with biochemical failure than other AR target gene signatures of similar size. Furthermore, it is enriched in malignant versus benign prostate tissues, compared with other signatures. To our knowledge, this profile represents the first demonstration of a distinct mechanism of androgen action with clinical relevance in PCa, offering a possible rationale to develop novel and more effective forms of ADT. Cancer Res; 71(5); 1978–88. ©2011 AACR.
Phase III Trial of Prophylactic Cranial Irradiation Compared With Observation in Patients With Locally Advanced Non–Small-Cell Lung Cancer: Neurocognitive and Quality-of-Life Analysis
Sun, A. , Bae, Kyounghwa, Gore, Elizabeth , Movsas, Benjamin , Wong, Stuart J. , Meyers, Christina A., Bonner, James A. , Schild, Steven E. , Gaspar, Laurie E., Bogart, J.A., Werner‐Wasik, Maria, Choy, Hak, Schild, Steven

Mayo Clinic

Journal of Clinical Oncology | December 7, 2010 | Volume: 29 | Issue: 3 | Pages: 279-286

10.1200/jco.2010.29.6053 | PMID 21135267 Get It

Purpose There are scant data regarding the effects of prophylactic cranial irradiation (PCI) on neurocognitive function (NCF) and quality of life (QOL). Radiation Therapy Oncology Group trial 0214 showed no overall survival (OS) benefit for PCI in stage III non–small-cell lung cancer (NSCLC) at 1 year. However, there was a significant decrease in brain metastases (BM). This analysis focuses on the impact of PCI on NCF and QOL. Patients and Methods Patients with stage III NSCLC who completed definitive therapy without progression were randomly assigned to PCI or observation. NCF was assessed with Mini-Mental Status Examination (MMSE), Activities of Daily Living Scale (ADLS), and Hopkins Verbal Learning Test (HVLT). QOL was assessed with the European Organisation for Research and Treatment of Cancer (EORTC) core tool (QOL Questionnaire-QLQC30) and brain module (QLQBN20). Results There were no statistically significant differences at 1 year between the two arms in any component of the EORTC-QLQC30 or QLQBN20 (P > .05), although a trend for greater decline in patient-reported cognitive functioning with PCI was noted. There were no significant differences in MMSE (P = .60) or ADLS (P = .88). However, for HVLT, there was greater decline in immediate recall (P = .03) and delayed recall (P = .008) in the PCI arm at 1 year. Conclusion PCI in stage III NSCLC significantly decreases the risk of BM without improving 1-year OS. There were no significant differences in global cognitive function (MMSE) or QOL after PCI, but there was a significant decline in memory (HVLT) at 1 year. This study provides prospective data regarding the relative risks and benefits of PCI in this setting and the need to use sensitive cognitive assessments.
Phase III Comparison of Prophylactic Cranial Irradiation Versus Observation in Patients With Locally Advanced Non–Small-Cell Lung Cancer: Primary Analysis of Radiation Therapy Oncology Group Study RTOG 0214
Gore, Elizabeth , Bae, Kyounghwa, Wong, Stuart J. , Sun, A. , Bonner, James A. , Schild, Steven E. , Gaspar, Laurie E., Bogart, J.A., Werner‐Wasik, Maria, Choy, Hak, Schild, Steven

Mayo Clinic

Journal of Clinical Oncology | December 7, 2010 | Volume: 29 | Issue: 3 | Pages: 272-278

10.1200/jco.2010.29.1609 | PMID 21135270 Get It

PurposeThis study was conducted to determine if prophylactic cranial irradiation (PCI) improves survival in locally advanced non–small-cell lung cancer (LA-NSCLC).Patients and MethodsPatients with stage III NSCLC without disease progression after treatment with surgery and/or radiation therapy (RT) with or without chemotherapy were eligible. Participants were stratified by stage (IIIA v IIIB), histology (nonsquamous v squamous), and therapy (surgery v none) and were randomly assigned to PCI or observation. PCI was delivered to 30 Gy in 15 fractions. The primary end point of the study was overall survival (OS). Secondary end points were disease-free survival (DFS), neurocognitive function (NCF), and quality of life. Kaplan-Meier and log-rank analyses were used for OS and DFS. The incidence of brain metastasis (BM) was evaluated with the logistic regression model.ResultsOverall, 356 patients were accrued of the targeted 1,058. The study was closed early because of slow accrual; 340 of the 356 patients were eligible. The 1-year OS (P = .86; 75.6% v 76.9% for PCI v observation) and 1-year DFS (P = .11; 56.4% v 51.2% for PCI v observation) were not significantly different. The hazard ratio for observation versus PCI was 1.03 (95% CI, 0.77 to 1.36). The 1-year rates of BM were significantly different (P = .004; 7.7% v 18.0% for PCI v observation). Patients in the observation arm were 2.52 times more likely to develop BM than those in the PCI arm (unadjusted odds ratio, 2.52; 95% CI, 1.32 to 4.80).ConclusionIn patients with stage III disease without progression of disease after therapy, PCI decreased the rate of BM but did not improve OS or DFS.
Temporal response of canine flexor tendon to limb suspension
Sun, Yulong , Thoreson, Andrew R. , Cha, Stephen S., Zhao, Chunfeng, An, Kai‐Nan, Amadio, Peter C. , Cha, Stephen S.

Mayo Clinic

Journal of Applied Physiology | October 15, 2010 | Volume: 109 | Issue: 6 | Pages: 1762-1768

10.1152/japplphysiol.00051.2010 | PMID 20947711 Get It

Tendon disuse, or stress deprivation, frequently accompanies clinical disorders and treatments, yet the metabolism of tendons subject to stress deprivation has rarely been investigated systematically. The effects of stress deprivation on canine flexor tendon were investigated in this study. One adult canine forepaw was suspended for 21 or 42 days. Control forepaws were collected from dogs that had no intervention on their limbs and paws. The expression of collagen I and III was not significantly altered in the tendons disused for 21 days but was significantly decreased at 42 days ( P < 0.03). The expression of collagen II, aggrecan, decorin, and fibronectin was significantly decreased in the tendons in the suspended limbs at 21 days ( P < 0.002) and further reduced at 42 days. With stress deprivation, the expression of matrix metalloproteinase 2 (MMP2) was significantly increased ( P < 0.004) at 21 and 42 days. The expression of MMP3 was significantly decreased at 21 and 42 days ( P < 0.03). The expression of MMP13 was not altered with stress deprivation at 21 and 42 days. The expression of MMP14 was significantly increased at 21 days ( P = 0.0015) and returned to the control level at 42 days. Tissue inhibitor of metalloproteinase 1 (TIMP1) expression was decreased after the limbs were suspended for 42 days ( P = 0.0043), but not 21 days. However, TIMP2 expression was not significantly different from control at 21 or 42 days. Furthermore, the cross-sectional area of the stress-deprived tendons at 42 days was decreased compared with the control group ( P < 0.01). The intervention method in this study did not result in any alteration of stiffness of the tendon. Our study demonstrated that stress deprivation decreases the anabolic process and increases the catabolic process of extracellular matrix in flexor tendon.